Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling
- PMID: 20207947
- PMCID: PMC2842056
- DOI: 10.1073/pnas.0911465107
Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling
Abstract
Biodegradable scaffolds seeded with bone marrow mononuclear cells (BMCs) are the earliest tissue-engineered vascular grafts (TEVGs) to be used clinically. These TEVGs transform into living blood vessels in vivo, with an endothelial cell (EC) lining invested by smooth muscle cells (SMCs); however, the process by which this occurs is unclear. To test if the seeded BMCs differentiate into the mature vascular cells of the neovessel, we implanted an immunodeficient mouse recipient with human BMC (hBMC)-seeded scaffolds. As in humans, TEVGs implanted in a mouse host as venous interposition grafts gradually transformed into living blood vessels over a 6-month time course. Seeded hBMCs, however, were no longer detectable within a few days of implantation. Instead, scaffolds were initially repopulated by mouse monocytes and subsequently repopulated by mouse SMCs and ECs. Seeded BMCs secreted significant amounts of monocyte chemoattractant protein-1 and increased early monocyte recruitment. These findings suggest TEVGs transform into functional neovessels via an inflammatory process of vascular remodeling.
Conflict of interest statement
Conflict of interest statement: T.S. receives partial funding from Gunze, a company that makes scaffolds for the clinical trials and animal work done in Japan. None of the funding for the work done in this manuscript was provided by Gunze.
Figures





Similar articles
-
Evidence for in vivo growth potential and vascular remodeling of tissue-engineered artery.Tissue Eng Part A. 2009 Apr;15(4):901-12. doi: 10.1089/ten.tea.2008.0172. Tissue Eng Part A. 2009. PMID: 18783324
-
The tissue-engineered vascular graft using bone marrow without culture.J Thorac Cardiovasc Surg. 2005 May;129(5):1064-70. doi: 10.1016/j.jtcvs.2004.10.030. J Thorac Cardiovasc Surg. 2005. PMID: 15867781
-
[Preliminary in vivo evaluation of tissue engineered venous grafts fabricated based on endothelial progenitor cells].Zhonghua Wai Ke Za Zhi. 2007 Apr 1;45(7):491-5. Zhonghua Wai Ke Za Zhi. 2007. PMID: 17686312 Chinese.
-
The Current Status of Tissue-Engineered Vascular Grafts.Cardiol Rev. 2015 Sep-Oct;23(5):236-9. doi: 10.1097/CRD.0000000000000060. Cardiol Rev. 2015. PMID: 25699981 Review.
-
Tissue engineered small-diameter vascular grafts.Clin Plast Surg. 2003 Oct;30(4):507-17. doi: 10.1016/s0094-1298(03)00069-5. Clin Plast Surg. 2003. PMID: 14621299 Review.
Cited by
-
Protein-engineered injectable hydrogel to improve retention of transplanted adipose-derived stem cells.Adv Healthc Mater. 2013 Mar;2(3):428-32. doi: 10.1002/adhm.201200293. Epub 2012 Sep 28. Adv Healthc Mater. 2013. PMID: 23184882 Free PMC article.
-
Self-assembling peptide scaffolds as innovative platforms for drug and cell delivery systems in cardiac regeneration.Drug Deliv Transl Res. 2013 Aug;3(4):330-5. doi: 10.1007/s13346-012-0125-8. Drug Deliv Transl Res. 2013. PMID: 25788281
-
Devitalized Stem Cell Microsheets for Sustainable Release of Osteogenic and Vasculogenic Growth Factors and Regulation of Anti-Inflammatory Immune Response.Adv Biosyst. 2017 Mar;1(3):1600011. doi: 10.1002/adbi.201600011. Epub 2017 Mar 7. Adv Biosyst. 2017. PMID: 30221188 Free PMC article.
-
Clinical Application for Tissue Engineering Focused on Materials.Biomedicines. 2022 Jun 17;10(6):1439. doi: 10.3390/biomedicines10061439. Biomedicines. 2022. PMID: 35740460 Free PMC article. Review.
-
Failure Analysis of TEVG's II: Late Failure and Entering the Regeneration Pathway.Cells. 2022 Mar 10;11(6):939. doi: 10.3390/cells11060939. Cells. 2022. PMID: 35326390 Free PMC article. Review.
References
-
- Kannan RY, Salacinski HJ, Butler PE, Hamilton G, Seifalian AM. Current status of prosthetic bypass grafts: A review. J Biomed Mater Res, Part B. 2005;74:570–581. - PubMed
-
- Fernandez G, et al. Prevalence of reoperation for pathway obstruction after Fontan operation. Ann Thorac Surg. 1989;48:654–659. - PubMed
-
- Alexi-Meskishvili V, et al. Optimal conduit size for extracardiac Fontan operation. Eur J Cardiothorac Surg. 2000;18:690–695. - PubMed
-
- Hibino N, Shin'oka T, Matsumura G, Ikada Y, Kurosawa H. The tissue-engineered vascular graft using bone marrow without culture. J Thorac Cardiovasc Surg. 2005;129:1064–1070. - PubMed
-
- Matsumura G, et al. Evaluation of tissue-engineered vascular autografts. Tissue Eng. 2006;12:3075–3083. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials